Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders
NCT ID: NCT00717392
Last Updated: 2013-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2008-09-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth
NCT04606966
Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder
NCT02301195
Computer-Mediated Intervention to Enhance Emotional Competence in Children With Autism in Schools
NCT05902832
Equine-assisted Therapy for Therapy-resistant Adolescents With Autism Spectrum Disorders, a Replicated AB-design
NCT05200351
Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder
NCT04772898
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of the current research is to evaluate the efficacy of 6 months of hippotherapy for children with developmental disabilities. The hypothesis is that children with developmental disabilities who are treated with hippotherapy for 6 months will show better outcomes than children with the same problems who are not treated with hippotherapy.
Assessment:
* BRIEF questionnaire
* Stony Brook Questionnaire
All questionnaires will be applied at the beginning of the study and after 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hippotherapy_ADHD
10 children with ADHD who receive hippotherapy
No interventions assigned to this group
Hippotherapy_ASD
10 children with ASD who receive hippotherapy
No interventions assigned to this group
Control_ADHD
10 children with ADHD who DO NOT receive hippotherapy
No interventions assigned to this group
Control_ASD
10 children with ASD who DO NOT receive hippotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of ADHD or ASD.
Exclusion Criteria
5 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Lidia Gabis MD
Director, The Weinberg Child Development Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lidia Gabis, MD
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer
Ramat Gan, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-08-5327-LG-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.